Literature DB >> 17118229

Lipids and diabetic nephropathy.

Rey F Rosario, Sharma Prabhakar.   

Abstract

Although several factors may mediate the development and progression of diabetic nephropathy, hyperlipidemia is now considered an independent and major determinant of progression of renal disease in diabetes. The following discussion focuses on the experimental evidence that incriminates hyperlipidemia as a pathogenic factor for diabetic nephropathy and the potential mechanisms that may mediate renal injury from hyperlipidemia, as well as the clinical studies involving therapeutic interventions for hyperlipidemia and their impact on progression of diabetic renal disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17118229     DOI: 10.1007/s11892-006-0079-7

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  54 in total

Review 1.  Exercise training and the cardiovascular consequences of type 2 diabetes and hypertension: plausible mechanisms for improving cardiovascular health.

Authors:  Kerry J Stewart
Journal:  JAMA       Date:  2002-10-02       Impact factor: 56.272

Review 2.  Modulation of glomerular sclerosis and interstitial fibrosis by native and modified lipoproteins.

Authors:  H J Gröne; J Hohbach; E F Gröne
Journal:  Kidney Int Suppl       Date:  1996-05       Impact factor: 10.545

3.  The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.

Authors: 
Journal:  Diabetes Care       Date:  2001-08       Impact factor: 19.112

4.  A placebo-controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD.

Authors:  Kevin P G Harris; David C Wheeler; Camilla C Chong
Journal:  Kidney Int       Date:  2002-04       Impact factor: 10.612

5.  Relationship of progressively increasing albuminuria to apoprotein(a) and blood pressure in type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetic patients.

Authors:  G Jerums; T J Allen; C Tsalamandris; A Akdeniz; A Sinha; R Gilbert; M E Cooper
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

Review 6.  Understanding the nature of renal disease progression.

Authors:  G Remuzzi; P Ruggenenti; A Benigni
Journal:  Kidney Int       Date:  1997-01       Impact factor: 10.612

7.  Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study.

Authors:  M A Gall; P Hougaard; K Borch-Johnsen; H H Parving
Journal:  BMJ       Date:  1997-03-15

8.  Multiple lipoprotein abnormalities in type I diabetic patients with renal disease.

Authors:  P H Groop; T Elliott; A Ekstrand; A Franssila-Kallunki; R Friedman; G C Viberti; M R Taskinen
Journal:  Diabetes       Date:  1996-07       Impact factor: 9.461

9.  Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors.

Authors:  M Ravid; L Neumann; M Lishner
Journal:  Kidney Int       Date:  1995-03       Impact factor: 10.612

10.  Apolipoprotein E genotypes and risk of diabetic nephropathy.

Authors:  T Onuma; L M Laffel; M C Angelico; A S Krolewski
Journal:  J Am Soc Nephrol       Date:  1996-07       Impact factor: 10.121

View more
  25 in total

Review 1.  Genetic associations in diabetic nephropathy.

Authors:  Antien L Mooyaart
Journal:  Clin Exp Nephrol       Date:  2013-10-16       Impact factor: 2.801

Review 2.  Role of triglyceride-rich lipoproteins in diabetic nephropathy.

Authors:  John C Rutledge; Kit F Ng; Hnin H Aung; Dennis W Wilson
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

3.  Role of triglyceride-rich lipoproteins in renal injury.

Authors:  Kit Fai Ng; Hnin Hnin Aung; John C Rutledge
Journal:  Contrib Nephrol       Date:  2011-06-09       Impact factor: 1.580

Review 4.  Soy-based renoprotection.

Authors:  Nancy J McGraw; Elaine S Krul; Elizabeth Grunz-Borgmann; Alan R Parrish
Journal:  World J Nephrol       Date:  2016-05-06

5.  Simvastatin ameliorates low-dose streptozotocin-induced type 2 diabetic nephropathy in an experimental rat model.

Authors:  Siwei Zhang; Huali Xu; Xiaofeng Yu; Yuchen Wang; Fanfan Sun; Dayuan Sui
Journal:  Int J Clin Exp Med       Date:  2015-04-15

6.  α-Lipoic acid protects diabetic apolipoprotein E-deficient mice from nephropathy.

Authors:  Xianwen Yi; Volker Nickeleit; Leighton R James; Nobuyo Maeda
Journal:  J Diabetes Complications       Date:  2010-08-30       Impact factor: 2.852

7.  Effects of combined ezetimibe and simvastatin therapy as compared with simvastatin alone in patients with type 2 diabetes: a prospective randomized double-blind clinical trial.

Authors:  Piero Ruggenenti; Dario Cattaneo; Stefano Rota; Ilian Iliev; Aneliya Parvanova; Olimpia Diadei; Bogdan Ene-Iordache; Silvia Ferrari; Antonio C Bossi; Roberto Trevisan; Antonio Belviso; Giuseppe Remuzzi
Journal:  Diabetes Care       Date:  2010-06-21       Impact factor: 19.112

Review 8.  Defining human diabetic nephropathy on the molecular level: integration of transcriptomic profiles with biological knowledge.

Authors:  Sebastian Martini; Felix Eichinger; Viji Nair; Matthias Kretzler
Journal:  Rev Endocr Metab Disord       Date:  2008-12       Impact factor: 6.514

9.  LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat.

Authors:  J L Figarola; S Loera; Y Weng; N Shanmugam; R Natarajan; S Rahbar
Journal:  Diabetologia       Date:  2008-03-04       Impact factor: 10.122

10.  Metformin ameliorates diabetic nephropathy in a rat model of low-dose streptozotocin-induced diabetes.

Authors:  Siwei Zhang; Huali Xu; Xiaofeng Yu; Yi Wu; Dayun Sui
Journal:  Exp Ther Med       Date:  2017-05-18       Impact factor: 2.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.